logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Dry Eye Syndromes

    FiltersReset Filters
    5 results

    • eysuvis

      (loteprednol etabonate)
      ALCON LABORATORIES, INC.
      Usage: EYSUVIS is a corticosteroid indicated for the short-term treatment (up to two weeks) of signs and symptoms associated with dry eye disease.

    • lacrisert

      (hydroxypropyl cellulose)
      Bausch & Lomb Incorporated
      Usage: LACRISERT is indicated for treating moderate to severe dry eye syndromes, including keratoconjunctivitis sicca, particularly in patients who do not respond adequately to artificial tears. It is also used for exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

    • miebo

      (Perfluorohexyloctane)
      Bausch & Lomb Incorporated
      Usage: MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for treating the signs and symptoms of dry eye disease (DED).

    • tyrvaya

      (varenicline)
      Oyster Point Pharma
      Usage: TYRVAYA (varenicline solution) nasal spray is indicated for treating the signs and symptoms associated with dry eye disease.

    • xiidra

      (Lifitegrast)
      Novartis Pharmaceuticals Corporation
      Usage: Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for treating the signs and symptoms of dry eye disease (DED).